Accelerate Diagnostics's revenue for the
three
months ended in Dec. 2023 was $3.03 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $12.06 Mil.
Accelerate Diagnostics's Revenue per Share for the
three
months ended in Dec. 2023 was $0.21.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.99.
Warning Sign:
Accelerate Diagnostics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Accelerate Diagnostics was -37.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -21.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -2.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 69.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Accelerate Diagnostics's highest 3-Year average Revenue per Share Growth Rate was 228.80% per year. The lowest was -81.80% per year. And the median was -2.10% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Accelerate Diagnostics's Revenue
For the Medical Devices subindustry, Accelerate Diagnostics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accelerate Diagnostics's Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Revenue distribution charts can be found below:
* The bar in red indicates where Accelerate Diagnostics's Revenue falls into.
Accelerate Diagnostics Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Accelerate Diagnostics Revenue Related Terms
Thank you for viewing the detailed overview of Accelerate Diagnostics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Accelerate Diagnostics (Accelerate Diagnostics) Business Description
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AXDX has been successfully added to your 